

Index

- abstract reasoning 76
 abulia 304, 311
 acalculia 294
 (N)-acetyl aspartate (NAA) 108–109
 acetylcholinesterase inhibitors
 see cholinesterase inhibitors
 achromatopsia 310
 acquired immunodeficiency
 syndrome (AIDS) 354
 acute confusional state *see* delirium
 age
 90 or older *see* oldest-old
 delirium risk and 369, 371
 age-associated cognitive decline 172, 189
 age-associated memory impairment
 172, 189
 age-related cognitive decline 189
 age-related white matter changes
 (ARWMC) 319–320
 age-specific incidence 120, 121
 age-specific prevalence 120
 oldest-old 257
 aggression 86–87
 management 233, 236–240
 aging
 animal studies 136
 cognitive decline 161, 188–189
 agitation, management 233, 236–240
 agnosia 232–236
 agrammatism 280
 graphia 77, 281, 309
 akinesia 305–306
 akinetic mutism 304, 346, 351
 alcohol consumption 124
 alcohol withdrawal 370
 alexia 77
 Hanja (Korean ideogram) 309, 310
 progressive non-fluent aphasia 281
 vascular dementia 309
 Alzheimer-type dementia 214–215
 Alzheimer's disease (AD) 56–66
 amnesic mild cognitive impairment
 as prodrome 161, 162
 amyloid hypothesis 28
 amyloid imaging 63, 111–112
 animal models 132–134, 136–137
 APOE 29–30, 57–58
 clinical features 5–6, 59–60
 CT 62
 costs 120
 definite 60
 diagnosis 59, 214
 diagnostic criteria 60, 144–145
 early-onset familial (FAD) 28–29
 epidemiology 56, 120–121
 functional MRI 109–110
 future directions 65–66
 genetics 28–30, 57–58
 hippocampal injury 104, 162
 history and neurological
 examination 60–61
 laboratory evaluation 61–62
 late onset 28, 29–30
 MRI 62, 104–105, 106, 108
 mental status examination 78–79
 neuroimaging 62–63
 neuropathological diagnosis 59
 neuropathology 58–59, 144–145
 neuropsychiatric symptoms 89–90
 neuropsychological testing 61
 overlap with dementia with Lewy
 bodies 15, 18
 pathogenesis 5, 28, 145
 PET 62–63, 102–103, 110–111
 possible 59, 60
 probable 59, 60
 progressive non-fluent aphasia
 and 282
 rapidly progressing 352–353
 risk factors 56–57, 121–126
 selective vulnerability 143
 SPECT 62, 102–103
 treatment 63–65, 214–215
 and variants 214–230
 vs. dementia with Lewy bodies
 13–14, 16–17
 vs. frontotemporal dementia
 46–47, 51
 vs. subcortical vascular dementia
 316–317
 Alzheimer's Disease Cooperative Study
 (ADCS) 181–182
 amnesia *see* memory impairment
 amyloid angiopathy *see* cerebral
 amyloid angiopathy
 amyloid β (A β ; A β 40) 28
 α -synuclein interaction 15
 APOE interactions 30
 CSF 62, 178
 mutations causing abnormal
 production 57
 neuritic plaques 58
 proteolytic formation 28, 29
 treatment targeting 65, 215
 amyloid β 42 (A β 42) 28, 29, 58
 animal studies 136
 CSF, Creutzfeldt–Jakob disease
 346–347
 neuritic plaques 144, 145
 pathogenic role 145
 vaccine 65
 amyloid hypothesis, Alzheimer's
 disease 28
 amyloid imaging 63, 111–112
 frontotemporal lobar dementia
 51, 111
 mild cognitive impairment 180
 pros and cons 112
 amyloid precursor protein (APP) 28
 animal studies 136
 protease-dependent processing 28, 29
 amyloid precursor protein gene
 (APP) 57
 alternative mRNA splicing 28
 invertebrate orthologs 136
 mouse (hAPP) models 132–133
 mutations 28
 amyotrophic lateral sclerosis (ALS),
 frontotemporal dementia with
 see frontotemporal dementia
 with motor neuron disease
 angiotensin-converting enzyme, DD
 genotype 336–337

Index

- angular gyrus syndrome 307
- animal models 131–137
 advantages 131–132
 CADASIL 336
 invertebrate 134–137
 vertebrate 132–134
- anomia
 corticobasal syndrome 294
 progressive non-fluent aphasia 280, 281
 semantic dementia 265–266, 267, 283
- anosmia 202, 203, 204
- anterior cerebral artery (ACA)
 territory infarction 303–306
- anti-AMPA receptor 378, 379, 381, 389
- anti-amphiphysin antibodies 378, 382, 386
- anti-CV2/CMRP-5 antibodies 353, 378, 382, 386
- anti-Hu antibodies 353, 378, 379, 382, 385–386
- anti-Ma1 antibodies 387
- anti-Ma2 antibodies 353, 378, 382, 387
- anti-Ma2 encephalitis 386–387, 388
- anti-neuropil antibodies 353–354, 378, 379, 382
- anti-NMDA receptor 378, 379, 381, 389
- anti-Ri antibodies 378, 386
- anti-voltage-gated potassium channel (VGKC) antibodies 353–354, 378, 379, 382, 386
- antibodies, paraneoplastic
see paraneoplastic antibodies
- anticipation, genetic 37
- antidepressants 95, 241
 Alzheimer's disease 64
 behavioral dyscontrol 237
 dementia with Lewy bodies 217
- antihypertensive therapy 126
- antioxidants 65, 124
- antiplatelet agents 339
- antipsychotic drugs (neuroleptics) 95
 atypical 95
 Alzheimer's disease 64
 behavioral dyscontrol 236–240
 dementia with Lewy bodies 19, 217, 218
 frontotemporal dementia 52
 Parkinson's disease with dementia 219, 223
 behavioral dyscontrol 236–240
 delirium 374
 sensitivity, dementia with Lewy bodies 11, 200, 217
- Anton's syndrome 310
- anxiety
 dementia with Lewy bodies 13
 management 233, 241
- anxiolytics, Alzheimer's disease 64
- apathy 87–88
 management 233, 240
- aphasia 77
 Alzheimer's disease 59
 corticobasal syndrome 292–293
 global 307
 management 232
 progressive *see* progressive aphasia
 progressive fluent *see* semantic dementia
 progressive non-fluent *see* progressive non-fluent aphasia
 transcortical 307, 309
 vascular dementia 307, 312
- APL-1 136
- apolipoprotein E (APOE) 29–30, 57–58
 based mouse models 133
 dementia with Lewy bodies and 18
 mild cognitive impairment and 178, 181–182
 primary progressive aphasia variants 284
 white matter lesions and 337
- APP *see* amyloid precursor protein
- APP-like protein (APPL) 136
- appetite disturbances 89
- apraxia 236
 corticobasal syndrome 293–294
 ideomotor *see* ideomotor apraxia
 progressive non-fluent aphasia 281
 progressive supranuclear palsy 297
 of speech 280, 281, 297–298
 vascular dementia 305–306
- L-arginine 340
- arteriosclerosis, small artery 315
- aspirin 339
- astrocytes
 thorny 151
 tufted 151
- astrocytic plaques 150, 151
- attention
 deficits, delirium 371, 372
 fluctuations, dementia with Lewy bodies 8–9
- autoimmune encephalopathies, rapidly progressing 353–354
- autonomic dysfunction
 dementia with Lewy bodies 10–11, 202
 as early symptoms 204, 208–209
 FTDP-17 208–209
 Parkinson's disease with dementia 10, 203
- Balint syndrome 215–216, 294, 310
- ballooned cells *see* Pick cells
- basal ganglia lesions 311–313
- basal temporal language area 309
- behavior, observations 3
- behavioral and psychological symptoms of dementia 236–240
- behavioral disturbances 85, 86–89
 assessment 85–86
 corticobasal syndrome 289–292
 first symptoms 2
 management 94–95, 233, 236–240
 progressive supranuclear palsy 297
 semantic dementia 266
 specific dementia syndromes 89–94
see also neuropsychiatric symptoms
- Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD) 85–86
- Behavioral Rating Scale for Dementia (BRSD) 85–86
- behavioral risk factors 123–125
- behavioral syndromes 86–88
- benzodiazepines 236, 374
- Binswanger's disease 213, 303, 316, 317
 genetic aspects 336–337
 lacunar changes with 316, 317
 neurological aspects 317–318
see also subcortical vascular dementia
- bismuth intoxication 348, 357
- blood oxygen level dependent (BOLD) signal 109

Index

- Borrelia burgdorferi* 355
 bovine spongiform encephalopathy (BSE) 231–232, 351
 boxers 125
 bradyphrenia, progressive
 supranuclear palsy 296
 brain biopsy, Creutzfeldt–Jakob disease 347
 Broca's aphasia 307
 bromocriptine 284
 CADASIL 213, 329–340
 animal models 336
 clinical features 330–332
 differential diagnosis 339
 epidemiology and risk factors 329–330
 genetic testing 339
 genetics 213, 337–338
 MRI 332–334
 management 339–340
 pathogenesis 338
 pathology 334–336, 337, 338
Caenorhabditis elegans 134–137
 California Verbal Learning Test (CVLT) 14
 callosal disconnection syndrome 306
 Camel and Cactus test 267–268
 cancer
 causes of delirium and cognitive dysfunction 380
 diagnosis 381
 rapidly progressing dementia 356
 see also paraneoplastic neurologic disorders
 cancer-related dementia 377
 Capgras syndrome 12–13, 88, 201
 capsular genu infarction 312–313
 carbamazepine 95, 236
 carbidopa, dementia with Lewy bodies 217
 cardiovascular risk factors
 122–123
 multiple 123
 caudate infarction 311–312
 CBD see corticobasal degeneration
 cerebral amyloid angiopathy (CAA) 58–59, 352
 cerebral amyloidosis, APP mutations 28
 cerebral atrophy
 Alzheimer's disease 62, 104–105
 CADASIL 333
 cerebrovascular disease-related 162
 cognitive impairment and 163
 dementia with Lewy bodies 16–17
 frontotemporal lobar degeneration 105, 106
 regional, imaging 104–107
 see also hippocampal injury/atrophy
 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy see CADASIL
 cerebral hemorrhage with amyloidosis, hereditary 28
 cerebral hypoperfusion, chronic 311
 cerebral infarction
 anterior cerebral artery territory 303–306
 borderzone 310–311
 cortical 303–311
 middle cerebral artery territory 306–308
 multiple cortical see multi-infarct dementia
 posterior cerebral artery territory 308–310
 silent 123, 162, 163
 single cortical 303
 subcortical 311–315
 see also multi-infarct dementia, stroke
 cerebral metabolism, regional 102–103
 cerebral microbleeds, in CADASIL 332–333
 cerebral perfusion, regional
 MRI and CT 103–104
 PET and SPECT 102–104
 cerebral small vessel disease 303, 329
 CADASIL 334–336
 dementia see subcortical vascular dementia
 pathology 315–316
 cerebral small vessels, anatomy 315
 cerebrospinal fluid (CSF) biomarkers
 Alzheimer's disease 62
 Creutzfeldt–Jakob disease 346–347
 mild cognitive impairment 178
 paraneoplastic limbic encephalitis 384
 cerebrovascular disease 162–167
 amnesic mild cognitive impairment 164–165, 167
 delirium 370
 as dementia risk factor 123
 depression and 319
 impact on cognition 162–164
 large vessels 303
 rapidly progressing dementia 354
 small vessels see cerebral small vessel disease
 spectrum of changes 162
 see also stroke, vascular dementia
 cerebrovascular risk factors 162–164
 impact on cognition 162–164
 charged multivesicular body protein 2B, *CHMP2B* mutations 32, 50
 Charles Bonnet syndrome 11–12
 cholinergic agonists 232
 cholinergic system
 delirium 371
 dementia with Lewy bodies 15–16
 PET 110–111
 cholinesterase inhibitors 232
 Alzheimer's disease 63, 64
 behavioral dyscontrol 236, 237
 delirium 371, 374
 dementia with Lewy bodies 13, 18–19, 217, 218
 frontotemporal dementia 52, 227, 228
 mild cognitive impairment 181–182, 184, 215
 neuropsychiatric symptoms 95
 Parkinson's disease with dementia 219, 223
 progressive supranuclear palsy 230
 vascular dementia 224, 225
 chorea, paraneoplastic 387–388
 chronic obstructive pulmonary disease 311
 cingulate cortex 105
 clinical features, major dementing diseases 6–5
 Clinician Assessment of Fluctuation 8
 clonazepam 242
 cognitive assessment
 delirium 371
 mental status examination 75–77
 oldest-old 259–260

Index

- cognitive function
 age-related decline 161, 188–189
 impact of cerebrovascular disease 162–164
 normative, oldest-old 258–259
- cognitive impairment
 CADASIL 331–332
 corticobasal degeneration 288–294
 delirium risk 367, 369
 management 232–236
 mild *see* mild cognitive impairment
 progressive supranuclear palsy 288, 294–296
- cognitive impairment no dementia (CIND) 189
 vascular (VCIND) 303, 319, 320
- cognitive reserve hypothesis 56–57
- cognitive training 123–124
- coiled bodies 150–151
- coiled tangles 151
- color vision disturbances 204, 310
- common disease common variant (CDCV) hypothesis 38
- complex genetic disorders 38
- compulsive behavior, vascular dementia 304–305
- computed tomography (CT)
 Alzheimer's disease 62
 regional cerebral perfusion 103–104
 regional tissue content 104, 112
- Confusion Assessment Method (CAM) 372–373
- confusional state, acute *see* delirium
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria 144
- constraint-induced movement therapy (CIMT) 236
- constructional tasks 77
- Contursi kindred 33
- coronary artery bypass grafting 311
- cortical blindness 310
- cortical thickness mapping 106
- corticobasal degeneration (CBD)
 205–207, 229
 clinical features 5–6
 cognitive deficits 288–294
 diagnosis 229
- differential diagnosis 198
 genetics 34–35
 management 229
 neuropsychiatric symptoms 93–94
 pathology 51, 147, 149–152, 288
 progressive non-fluent aphasia and 47, 49, 282
 rapidly progressing 352–353
 selective vulnerability 143
 underlying biology 5
- corticobasal degeneration syndrome (CBDS) *see* corticobasal syndrome
- corticobasal syndrome (CBS)
 205–207, 229–230
 apraxia 293–294
 asymmetry and laterality 293
 case reports 289–291
 clinical features 206–207
 diagnostic criteria 206
 differential diagnosis 198
 early clinical features 207
 frontal/behavioral change 289–292
 genetics 33, 34
 language 292–293
 management 229–230
 overlap with frontotemporal dementia 288–289
 progressive non-fluent aphasia and 285
 progressive supranuclear palsy and 288, 297–298
 visuospatial impairment 294
- costs, economic
 delirium 367–368
 dementia 120
- Creutzfeldt–Jakob disease (CJD)
 230–231, 345–350
 brain biopsy 347
 clinical features 6–5
 diagnosis 231
 epidemiology 345
 familial (fCJD) 350–351
 genetics 35–36
 management 231, 351–352
 mechanisms 5, 348–349
 MRI diagnosis 347, 351
 neuroimaging 107, 108
 putative biomarkers 346–347
 sporadic (sCJD) 345–350
 demographics 345–346
 diagnosis 346, 348
 differential diagnosis 348, 349
 genetic markers 349–350
 variant (vCJD) 231–232, 351
- Cryptococcus* infections 355
- CSF *see* cerebrospinal Acid
- CT *see* computed tomography
- cytotoxic T cells, paraneoplastic disorders 377–379
- dardarin 34
- daytime somnolence, excessive
 see hypersomnia/
 hypersomnolence
- default mode network 110
- delirium 308, 367–375
 clinical characteristics 368–369
 definition 367–368
 diagnosis and evaluation 368, 371–373, 374
 diagnostic scales 372–373
 epidemiology, morbidity and costs 367–368
 etiologies 370–371, 380
 future directions 374–375
 investigations 373
 management 373–374
 pathophysiology 371
 postoperative 367, 369
 risk factors 369–370
- delusional misidentification syndromes 2, 88, 201
- delusions 88
 dementia with Lewy bodies 12–13
 management 233, 240–241
- dementia
 CADASIL 331–332
 delirium risk 367, 369
 progressive supranuclear palsy 297
 see also cognitive impairment,
 specific types of dementia
- dementia lacking distinctive histopathology (DLDH) 149, 282
- dementia pugilistica 125
- dementia with Lewy bodies (DLB)
 7–20, 197–202, 213, 216–223
 autonomic dysfunction 10–11, 202
 clinical features 5–6, 7–14, 200–202
 diagnosis 216
 diagnostic criteria 7–8, 200
 differential diagnosis 198
 early clinical features 203–204
 epidemiology 7
 fluctuations in attention 8–9, 202
 functional MRI 17, 110
 future research 19–20
 genetics 17–18, 33–34

Index

- management 18–19, 216–223
 mental status examination 80
 neuroimaging 16–17, 103, 108
 neuropathology 14–15, 152–153
 neuropsychiatric symptoms 11–13, 92–93, 201
 neurotransmitters 15–16
 overlap with Alzheimer's disease 15, 18
 parkinsonism 9, 201
 prodrome 19–20, 203
 rapidly progressing 352–353
 REM sleep behavior disorder 9–10, 200, 201
 selective vulnerability 143
 sensitivity to medication and infection 11
 underlying biology 5
 vs. Alzheimer's disease 13–14, 16–17
 vs. delirium 370
 vs. Parkinson's disease with dementia 197–200, 216
- depression 87
 cerebrovascular disease and 319
 as dementia risk factor 125
 dementia with Lewy bodies 13
 history taking 2
 management 233, 241
 mental status examination 77
 post-stroke 308
 presenting as dementia 357
- diabetes mellitus 122
- diagnosis
 clinical 1–6
 oldest-old 260
- diencephalic amnesia 313–314
- dietary risk factors 57, 124–125
- diffusion tensor imaging (DTI)
 107–108, 112
 CADASIL 333–334, 335
 dementia with Lewy bodies 16–17
- diffusion-weighted imaging (DWI)
 107–108, 112
- digit span tests 76
- disinhibited behavior 86–87
 management 233, 240
 vascular dementia 304–305
- DJ-1* gene 34
- DLB *see* dementia with Lewy bodies
- donepezil
 Alzheimer's disease 63, 64
 dementia with Lewy bodies 18–19
- mild cognitive impairment 181–182, 184
 neuropsychiatric symptoms 95
- dopamine agonists 19, 217, 223
- dopaminergic system
 dementia with Lewy bodies 16
 PET 111
- dorsolateral prefrontal cortex (DLPFC) 162
 damage, vascular dementia 306–307
 disruption of neural circuits 165
 white matter hyperintensities and 165–166
- Down's syndrome
 Alzheimer's disease 28, 57
 β -amyloid protein 28
- doxycycline 352
- driving, discontinuation 64
- Drosophila melanogaster* 134–137
- drug misuse 370
- dysosmia 204
- dysphagia 61
- dysprosody 77
see also prosody, emotional
- eating behavior, disturbances in 89
- education, dementia risk and 122
- EFA6A antigen 389
- electroencephalography (EEG)
 Alzheimer's disease 62
 Creutzfeldt–Jakob disease 346, 347
 dementia with Lewy bodies 9
 paraneoplastic limbic encephalitis 383
- emotional lability 233, 241
- encephalomyelitis, paraneoplastic 380
- enteroviral meningoencephalitis 355
- entorhinal cortex 104, 178, 272
- epidemiology 120–127
see also prevalence
- estrogen replacement therapy 65, 126–127
- ethnic differences 121–122
- euphoria 89
- executive dysfunction
 management 236
 progressive non-fluent aphasia 280
- progressive supranuclear palsy 296
 vascular dementia 306–307, 318
- executive function (EF), mental status examination 75–76
- exercise 57, 124
- extrapyramidal symptoms
see parkinsonism
- falls, as early symptom 2
- fatal familial insomnia (FFI) 35, 36, 350–351
- fatal insomnia, sporadic (sFI) 350
- fatigue, affecting cognitive testing 259–260
- FDDNP (fluoro-dicgano-dimethylamino-naphthalenyl-propene) 179
- fish consumption 124–125
- flexibility, mental 76
- fluctuations
 dementia with Lewy bodies 8–9, 202
 as early symptom 204
 Parkinson's disease with dementia 203
- fluency 76
- fluoro-dicyano-dimethylamino-naphthalenyl-propene (FDDNP) 179
- flupertine 231
- folic acid supplements 123
- forgetfulness *see* memory impairment
- 14-3-3 protein 231, 346–347
- fractional anisotropy (FA) 108
- frontal lobe dysfunction
 cerebral infarction 303–305
 corticobasal syndrome 289–292
see also executive dysfunction
- frontotemporal dementia (FTD)
 45–52, 213–214
 animal models 134, 136–137
 behavioral or frontal variant (bv-FTD) 45, 47–48, 227
 clinical features 47–48
 diagnosis 227
 management 227
 neuroimaging 51, 105
 pathology 146, 147, 148, 149
 selective vulnerability 143
 clinical features 5–6, 47

Index

- frontotemporal dementia (FTD)
 (cont.)
 diagnosis 46–47
 functional MRI 110
 genetics 30–33, 49–50
 mental status examination 79
 neuroimaging 103, 108
 neuropsychiatric symptoms 91–92
 overlap with corticobasal
 degeneration 288–289
 with parkinsonism 46
 pathology 145–149
 prodrome 191
 temporal variant (tv-FTD)
 see semantic dementia
 treatment 52, 228
 underlying biology 5
- frontotemporal dementia with motor
 neuron disease (FTD-MND)
 46, 48
 clinical features 47
 genetics 50
 pathology 51, 146, 149
 rapidly progressing 352–353
 selective vulnerability 143
- frontotemporal dementia with
 parkinsonism linked to
 chromosome 17 (FTDP-17)
 207–209
 clinical features 207
 differential diagnosis 198
 early clinical features 208–209
 genetics 31, 49
 pathology 147
- frontotemporal lobar degeneration
 (FTLD) 45–52
 amyloid imaging 51, 111
 clinical syndromes 47
 genetics 30–31, 49–50
 history 45–46
 mental status examination
 79–80
 neuroimaging 51, 103, 105–106
 neuropsychiatric symptoms
 91–92
 pathology 50–51, 145–149
 selective vulnerability 143
 subtype classification 45, 46
 tau-positive (FTLD-T) 146, 147
 treatment 52, 224–230
 ubiquitin-positive/tau-negative
 (FTLD-U) 146, 147–149, 150
- FTDP-17 *see* frontotemporal
 dementia with parkinsonism
 linked to chromosome 17
- functional assessment 2, 77–78
- functional magnetic resonance
 imaging (fMRI) 109–110, 112
 dementia with Lewy bodies 17, 110
 dorsolateral prefrontal cortex
 activation 165–166
 resting state 110
- galantamine
 Alzheimer's disease 63, 64
 mild cognitive impairment 182
 neuropsychiatric symptoms 95
- gaze palsy, vertical supranuclear
 205, 207
- gender differences
 dementia in oldest-old 256–258
 dementia risk 121
 progressive non-fluent aphasia
 282–283
- genetic disorders, complex 38
- genetic testing 4
- genetics *see* neurogenetics
- Gerstmann–Straussler–Scheinker
 disease (GSS) 35, 36,
 350–351
- Gerstmann's syndrome 309
- glial cytoplasmic inclusions 153–154
- glial nuclear inclusions 153–154
- globose tangles 151
- glucose metabolism, regional brain
 102–103
- granular osmophilic material (GOM)
 334, 336
- granuovacuolar degeneration 58–59
- Hachinski Ischemic Score (HIS)
 302, 321
- hallucinations 88
 extracampion 12
 management 233, 240–241
see also visual hallucinations
- haplo-insufficiency 33, 50
- Hashimoto's encephalopathy 354
- head trauma 125–126
- hearing loss 259–260
- heart failure 311
- heavy metal intoxication 356
- hereditary cerebral hemorrhage
 with amyloidosis 28
- ^{99m}Tc-hexamethylpropyleneamine
 oxime (HMPAO) 102
- hippocampal injury/atrophy
 Alzheimer's disease 104, 162
 CADASIL 331–332
 mild cognitive impairment 178, 179
 semantic dementia 272
 severe and mild cognitive
 impairment (MCI-HA)
 164–165
- hippocampus 162
- history, clinical 1–2
- hoarding 304–305
- homocysteine 123
- hormone replacement therapy 65,
 126–127
- Human Genome Project 27, 38
- human immunodeficiency virus
 (HIV) 354
- huntingtin (Htt) 37, 154
- Huntington's disease (HD) 36–37,
 143, 154
- hydergine 224, 225
- hyperphagia 241
- hypersomnia/hypersomnolence
 as early clinical feature 201,
 203–204
 management 233, 242
- hypertension
 cerebral small vessel pathology 315
 cognitive impairment and 163
 dementia risk 122, 162–163
 genetic aspects of white matter
 lesions 336–337
- hypokinesia 305–306
- hypomania 89
- hypothalamic syndrome, neural crest
 tumors 391
- ideomotor apraxia
 corticobasal syndrome 293
 pathophysiology 306, 307
 vascular dementia 305–306, 307
- illusions, visual 12, 201, 236
- imitation behavior 305
- impulsive behavior, vascular dementia
 304–305
- incidence, dementia 120, 121
- inclusion body myopathy associated
 with Paget's disease and
 frontotemporal dementia
 (IBMPFD) 31–32, 50

Index

- infarction *see* cerebral infarction
- infectious diseases
 delirium 370, 371
 rapidly progressing dementia 354–356
 sensitivity, dementia with Lewy bodies 11
- inhibition, response 76
- insomnia
 management 233, 241
see also sleep disturbances
- intensive care unit, delirium 367, 372–373
- International Hap Map Project 38
- invertebrate models 134–137
 dementia 136–137
 therapeutic potential 137
- investigations 4–6
- ischemic episodes, in CADASIL 330
- ischemic-hypoperfusive vascular dementia (VaD) 310–311
- ischemic white matter changes 316
- IT15* (gene for huntingtin) 37
- Jakob–Creutzfeldt disease
see Creutzfeldt–Jakob disease
- JC virus infections 355
- Kuf's disease 356
- kuru 36
- laboratory testing 4–6
- lacunar infarction 315–316
 CADASIL 330, 332, 333, 334–335
- lacunar state 303, 316
 neurological aspects 317–318
 white matter changes with 316, 317
see also subcortical vascular dementia
- language
 areas of brain 307
 mental status examination 76–77
- language problems
 Alzheimer's disease 59
 corticobasal syndrome 292–293
 as first symptoms 2
 progressive supranuclear palsy 297
 subcortical vascular dementia 318
see also aphasia
- late-life forgetfulness 189
- Leisure World Cohort Study 254
- lentiform nucleus infarction 312
- leucine-rich repeat kinase 2, *LRRK2* mutations 34
- leukoaraiosis 316
- levodopa (L-dopa)
 dementia with Lewy bodies 19, 217, 218
 Parkinson's disease with dementia 219, 223
- Lewy bodies (LB) 14, 152
 Alzheimer's pathology with 15
 brainstem 152, 153
 cortical 152, 153
- Lewy body dementia *see* dementia with Lewy bodies
- Lewy neurites 152, 153
- lexical decision task, semantic dementia 268–269
- lifestyle
 modification, mild cognitive impairment 184
 risk factors 123–125
- limb apraxia
 progressive non-fluent aphasia 281
 progressive supranuclear palsy 297
- limbic, diencephalon and brainstem encephalitis (Ma2 encephalitis), paraneoplastic 386–387, 388
- limbic encephalitis
 differential diagnosis 385
 paraneoplastic *see* paraneoplastic limbic encephalitis
 with anti-VGKC antibodies (non-paraneoplastic) 384, 386
- limited dementia 189
- linkage analysis 27
- lipohyalinosis 315
- lithium 227
- lod score 27
- logopenia, progressive supranuclear palsy 297
- logopenic progressive aphasia (LPA) 283–284
- Lyme disease 355
- lymphoma
 intravascular 354, 356
 primary CNS (PCNSL) 356
- mad cow disease 231–232
- see also* bovine spongiform encephalopathy
- magnetic resonance imaging (MRI) 4–6, 112
 Alzheimer's disease
see Alzheimer's disease
 CADASIL 332–334
 cortical thickness mapping 106
 Creutzfeldt–Jakob disease 347, 351
 dementia with Lewy bodies 16–17
 diffusion tensor imaging
see diffusion tensor imaging
 diffusion-weighted imaging (DWI) 107–108, 112
 functional *see* functional magnetic resonance imaging
 iron-dependent T₂-weighted contrast 109
 magnetic resonance spectroscopy with 108–109, 112
 paraneoplastic neurological disorders 381, 383, 384, 387, 388
 rapidly progressing dementias 348, 349
 regional cerebral perfusion 103–104, 112
 regional tissue content 104–107
 risk factors for dementia 123
 voxel-based morphometry (VBM) 105–106
- magnetic resonance spectroscopy (MRS) 108–109, 112
- malignant disease *see* cancer
- manganese toxicity 356
- mania 89, 306
- MCI *see* mild cognitive impairment
- medical examination 3
- medical history, past 2
- medications
 causing delirium 370, 371
 past history 2
 sensitivity, dementia with Lewy bodies 11, 19
- melatonin 218, 240–241, 242
- memantine
 Alzheimer's disease 63, 64
 behavioral dyscontrol 236, 237
 dementia with Lewy bodies 217
 neuropsychiatric symptoms 95
- memory 161–162
 episodic 75, 161–162
 explicit 161

Index

- memory (cont.)
 implicit 161
 mental status examination 75
 semantic *see* semantic memory
 working 76
- memory impairment
 Alzheimer's disease 59
 corticobasal syndrome 294
 as first symptom 2
 management 232, 233
 progressive supranuclear palsy 296
 semantic dementia 266, 267–272
 vascular dementia 309, 312,
 313–315, 318
see also senescent forgetfulness
- mental activity 123–124
- mental status examination 2–3,
 74–81
 cognitive 75–77
 delirium 372
 differential diagnosis 78–81
 functional status 77–78
 suggested 78
see also neuropsychological profiles
- meta-iodoenzylguanidine (MIBG)
 cardiac scintigraphy 10
- metabolic disorders 356–357, 370
- metabolic syndrome 123
- microtubule-associated protein tau,
 the *MAPT* gene
 invertebrate studies 136–137
 mutations 30–31, 32, 35, 49
 polymorphisms 35
 transgenic mouse models 133–134
see also tau
- middle cerebral artery territory
 infarction 306–308
- migraine
 CADASIL 330
 familial hemiplegic (FHM) 339
- mild behavioral impairment
 (MBI) 191
- mild cognitive impairment
 (MCI) 172–185
 Alzheimer's disease prodrome
 161, 162
 amnesic (aMCI) (multiple domain)
 conceptualization 190
 progression 177–178
 amnesic (aMCI) (single
 domain) 191
 cerebrovascular contributions
 161–167
 clinical trial data 180–183
 conceptualization 190
 conversion to dementia
 192–193
 diagnosis 175–176
 evidence for vascular 164–165
 management 215
 memory impairment 161–162
 neuropathology 179–180, 193
 outcomes 176–177, 178
 APOE and progression 178, 181
 application to clinical practice
 183–184
 cases 173, 175–176
 clinical severity 177
 clinical trials 161, 180–183
 conceptualization 161, 188–189
 corticobasal syndrome
 prodrome 207
 counseling patients 184
 CSF and plasma biomarkers 178
 dementia with Lewy bodies and
 19–20, 203
 diagnostic criteria and diagnosis
 174–176, 190
 dysexecutive 191, 192, 193
 epidemiology 172–174
 FTDP-17 prodrome 208
 functional MRI 110
 future research prospects 184–185
 historical context 172
 introduction of term 188, 189
 language 192
 MRI 105, 106, 108, 178, 179
 multiple cognitive domains
 (MCI-MCDT; md-MCI;
 memory plus) 192
 conceptualization 190
 conversion to dementia 192–193
 neuropathology 179–180
 neuropsychiatric symptoms
 89, 90
 non-amnesic (naMCI)
 (multiple domain) 176
 conceptualization 190
 diagnosis 175
 non-amnesic (naMCI) (single
 domain) 176, 191–192
 conceptualization 190
 outcomes 176–177
 Parkinson's disease with dementia
 prodrome 203
 PET 102, 178–179
 predictors of progression 177–179
 progressive supranuclear palsy
 prodrome 205
 with severe hippocampal atrophy
 (MCI-HA) 164–165
 with severe white matter
 hyperintensities
 (MCI-WMH) 164–165
 subgroups 161, 188–194
 clinical outcomes 192–193
 conceptualization 190–191
 conversion diagnoses 190
 conversion to dementia 192–193
 mortality 193
 neuroimaging 192
 neuropathology 193
 prevalence 191
 vascular 303, 319, 320
 visuospatial 192
- Mini-Mental State Examination
 (MMSE) 2, 74–75
 delirium 372
 dementia with Lewy bodies 14
 oldest-old 258
- minimal dementia 189
- misidentification errors 200, 236
- mood disorders
 dementia with Lewy bodies 13
see also depression, mania
- mood-stabilizing agents 95
- Morvan's syndrome 382, 386
- motor/extrapyramidal symptoms
see parkinsonism
- motor hyperactivity 88
- motor impersistence 305–306
- motor intentional disorders 305–307
- motor neuron disease (MND),
 frontotemporal dementia
 with *see* frontotemporal
 dementia with motor neuron
 disease
- motor problems, as early symptoms 2
- motor speech disorder, pure 284
- mouse models 132–134
 Alzheimer's disease 132–134
 frontotemporal dementia 134
- MRI *see* magnetic resonance imaging
- multi-infarct dementia 213, 303, 304
- multiple system atrophy 14, 143,
 153–154
- mutism, akinetic *see* akinetic mutism
- mycobacterial infections 355
- myoclonus 61
- N-acetyl-aspartate (NAA) 108–109

Index

- National Institute on Aging/Ronald and Nancy Reagan Institute of the Alzheimer's Association (NIA-Reagan) criteria 144–145
- naturopathic medications 65
- neglect
 unilateral spatial 308
 visuospatial 309–310
- neural crest tumors, paraneoplastic syndromes of children with 389–391
- neuritic plaques (NPs) 58
 Alzheimer's disease 144–145
 dementia with Lewy bodies 152–153
- neurofibrillary tangles (NFTs) 31, 58
 Alzheimer's disease 59, 144–145
 dementia with Lewy bodies 152–153
 progressive supranuclear palsy 151
- neurogenetics 27–38
 future 37–38
 techniques 27
- neuroimaging 4–6, 101–113
 alternative metabolic and functional analyses 108–112
 alternative structural analyses 107–108
 regional glucose metabolism and brain perfusion 102–104
 regional tissue content/atrophy 104–107
 techniques compared 112
 see specific modalities
- neuroleptic agents *see* antipsychotic drugs
- neurological examination 3
- neuron-specific enolase (NSE) 231, 346–347
- neuronal ceroid lipofuscinosis 356
- neuronal cytoplasmic inclusions (NCIs) 153–154
- neuronal intermediate filament inclusion disease (NIFID) 149
- neuronal nuclear inclusions 153–154
- neuropathology 142–155
- Neuropsychiatric Inventory (NPI) 85–86
- neuropsychiatric symptoms 85–95
 assessment 85–86
- CADASIL 331
 dementia with Lewy bodies 11–13, 92–93, 201
 mental status examination 77
 progressive supranuclear palsy 297
 specific dementia syndromes 89–94
 treatment 94–95
 vascular dementia 90–91, 308, 318–319
 see also behavioral disturbances
- neuropsychological profiles
 Alzheimer's disease 61
 dementia with Lewy bodies 13–14
 normative, for oldest-old 258–259, 261
 progressive non-fluent aphasia 281
 semantic dementia 267–272
 see also mental status examination
- neurosyphilis 355
- neurotransmitters
 dementia with Lewy bodies 15–16
 PET 110–111, 112
- niacin deficiency 356
- 90+ Study, The 254–261
 cognitive assessment 259–260
 dementia prevalence 256–258
 dementia screening 258
 normative neuropsychological data 256, 258–259
 participants and methodology 254, 255, 256
 see also oldest-old
- NMDA-receptor antagonists 63, 64, 95
- non-steroidal anti-inflammatory drugs (NSAIDs) 65, 126
- non-vasculitic autoimmune meningoencephalitis (NAIM) 354
- Notch3* mutations 329, 337–338
 animal models 334
 diagnostic testing 339
 pathophysiological effects 338
- novel tool test 270
- object decision task, semantic dementia 268, 269
- object-use apraxia
 corticobasal syndrome 293
 semantic dementia 266, 270–271
- oldest-old 254–261
 cognitive assessment 259–260
 dementia prevalence 254–258
 diagnostic considerations 260
- neuropathology of dementia 260
- normative neuropsychological data 256, 258–259
- numbers in population 255
- research challenges 260–261
- research questions 254
- screening for dementia 258
- omega 3 polyunsaturated fatty acids (PUFA) 124–125
- onconeural antigens, antibodies against 377–379
 see also paraneoplastic antibodies
- One Day Fluctuation Assessment Scale 8
- opsoclonus–myoclonus (–ataxia) 380, 389–391
- orbitofrontal lobe damage, anterior cerebral artery infarction 304–305
- orthostatic hypotension 10, 203
 management 217, 233
- ovarian teratoma, encephalitis with 389
- palipsychism 313
- pallidopontonigral degeneration 49, 208–209
- PAR-1*, gene for serine/threonine kinase 136–137
- paraneoplastic antibodies 378, 381–382
 onconeural antigens 377–379
 paraneoplastic limbic encephalitis 379, 384–386
 see specific antibodies
- paraneoplastic limbic encephalitis (PLE) 353, 377, 383–386
 antibodies 382
 diagnosis 379, 380, 384–386
 investigations 381, 383–384
 pathology 378, 384
- paraneoplastic neurologic disorders (PND) 353, 377–391
 antibody testing 381–382
 children with neural crest tumors 389–391
 diagnostic criteria 382–383
 frequency 377
 pathogenesis 377–380
 symptom presentation and diagnosis 380–383
 treatment strategies 390, 391
- paraoxinase, *PON1* LL genotype 337

Index

- parasomnias 242
PARK1-8 mutations 17
parkin gene 17, 34
 parkinsonian-related dementias
 comparison between 198
 early clinical features 197–209
 genetics 33–35
 parkinsonism (motor/extrapyramidal symptoms)
 corticobasal syndrome 206
 delirium with 372
 dementia with Lewy bodies 9, 201
 as early symptom 203, 205, 207
 FTDP-17 208
 management 233
 Parkinson's disease with dementia 9, 203
 progressive supranuclear palsy 205
 Parkinson's disease with dementia (PDD) 202–204, 213, 223
 autonomic dysfunction 10, 203
 clinical features 202–203
 diagnosis 7–8, 223
 diagnostic criteria 202
 differential diagnosis 198
 early clinical features 203–204
 genetics 17–18
 imaging 111
 management 219, 223
 motor/extrapyramidal symptoms 9, 203
 neuropsychiatric symptoms 92–93, 202
 neurotransmitters 15–16
 pathology 14
 prodrome 191
 vs. dementia with Lewy bodies 197–200, 216
 periodic limb movement disorder 233, 241
 periodic sharp-wave complexes 346
 perirhinal cortex, semantic dementia 272–273
 perseveration 318
 motor 305–306
 person recognition problems, semantic dementia 267
 personality changes
 corticobasal syndrome 289–292
 as first symptoms 2
 progressive supranuclear palsy 297
 semantic dementia 266
 PET *see* positron emission tomography
 phonemic paraphasias 280, 281
 physical activity 57, 124
 Pick bodies 51, 147, 148
 Pick cells (ballooned cells) 51, 147, 148, 151
 Pick's disease 45–46
 historical background 264
 overlap with corticobasal degeneration 289
 pathology 50–51, 147, 148, 150
 semantic dementia 273, 274
PINK1 (gene for PTEN-induced kinase1) 17, 34
 Pittsburgh compound B (PIB) 51, 63, 111–112, 179
 polyglutamine repeats 37
 polyunsaturated fatty acids (PUFA) 124–125
 positional cloning 27
 positron emission tomography (PET) 6
 Alzheimer's disease 62–63, 102–103
 amyloid imaging *see* amyloid imaging
 cerebral glucose metabolism 102–103, 112
 frontotemporal dementia 51
 mild cognitive impairment 102, 178–179
 neurotransmitter systems 110–111, 112
 paraneoplastic neurologic disorders 381, 383–384, 389
 postoperative delirium 367, 369
 post-stroke dementia 302
 posterior cerebral artery territory infarction 308–310
 posterior cortical atrophy 215–216
 presenilin (genes *PS1* and *PS2*) 29, 57
 mouse models 133
 prevalence
 dementia 120, 121
 dementia in oldest-old 254–258
 mild cognitive impairment 172–174
 mild cognitive impairment subgroups 191
 vascular dementia 302
 prevention of dementia
 medications for 126–127
 mild cognitive impairment trials 180–183
 potential impact 120–121
 primary progressive aphasia (PPA) 46, 227–229, 279
 bimodal distribution 264
 conceptualization 284
 genetics 33, 284
 management 229, 284
 mild cognitive impairment and 192
 overlap with corticobasal degeneration 289
 variants 283–284
 see also progressive non-fluent aphasia, semantic dementia
 prion diseases 214, 345–352
 diagnosis and management 230–232
 epidemiology 345
 genetics 35–36, 350–351
 mechanisms 348–349
 treatment 351–352
 see also Creutzfeldt–Jakob disease
 prion protein
 PrP^C 349
 function 349
 PrP^{Sc} 35–36, 349
 direct detection assays 347–348
 treatments targeting 351–352
 type 1 or 2 350
 variant Creutzfeldt–Jakob disease 351
PRNP gene
 mutations 35–36, 350–351
 polymorphisms 36, 349–350, 351
 progranulin, *PGRN* mutations 32–33, 49–50, 52, 149
 progressive aphasia 279
 logopenic 283–284
 primary *see* primary progressive aphasia
 progressive asymmetrical rigidity and apraxia (PARA) syndrome 229–230
 progressive fluent aphasia *see* semantic dementia
 progressive limbic encephalopathy (PLE) *see* paraneoplastic limbic encephalitis

Index

- progressive non-fluent aphasia (PNFA) 46, 48–49, 227–229, 279–285
 behavioral or frontal variant (bv-FTD) 147
 case report 285
 classification 45
 clinical features 5–6, 47, 48–49
 corticobasal degeneration and 47, 49, 282
 definition and diagnostic criteria 280–281
 demographics 282–283
 genetics 33
 management 229, 284
 neuroimaging 281
 neurological examination 281
 neuropsychiatric symptoms 91–92
 pathology 146, 149, 282
 progressive supranuclear palsy and 47, 49, 282, 297
 selective vulnerability 143
 underlying biology 5
- progressive perceptual-motor syndrome 229–230
- progressive posterior cortical syndrome 215–216
- progressive simultanagnosia 215–216
- progressive supranuclear palsy (PSP) 204–205, 230
 clinical features 5–6, 204–205
 cognitive deficits 288, 294
 corticobasal syndrome and 288, 297–298
 diagnosis 230
 diagnostic criteria 204
 differential diagnosis 198
 early clinical features 205
 genetics 34–35
 historical aspects 294–296
 management 230
 mental status examination 79, 80–81
 neuropsychiatric symptoms 93–94, 205
 pathology 51, 147, 149–152, 288
 progressive non-fluent aphasia and 47, 49, 282, 297
 rapidly progressing 352–353
 selective vulnerability 143
 underlying biology 5
- progressive visuospatial syndrome 215–216
- prosody, emotional 293, 308
- prosopagnosia 309, 310
- protein misfolding cyclic amplification (PMCA) 348
- PrP *see* prion protein
- PSAPP mice 133
- pseudobulbar affect 233, 241
- PSP *see* progressive supranuclear palsy
- psychiatric disorders 357
- psychiatric history 2
- psychiatric observations 3
- psychiatric symptoms
 see neuropsychiatric symptoms
- psychosis 88
- psychosocial risk factors 125
- pure motor speech disorder 284
- puromycin-sensitive aminopeptidase 137
- Pyramids and Palm Trees Test 267–268
- questionable dementia 189
- quinacrine 231, 351–352
- racial differences 121–122
- radiation therapy, whole brain (WBRT) 356
- radiologic risk factors 123
- raloxifene 127
- rapid eye movement *see* REM
- rapidly progressing dementias (RPDs) 345–357
 autoimmune encephalopathies 353–354
 diagnosis 357
 differential diagnosis 348, 349
 infectious diseases 354–356
 malignancies 356
 non-organic (psychiatric) causes 357
 non-prion neurodegenerative diseases 352–353
 toxic-metabolic conditions 356–357
 vascular disease 354
see also Creutzfeldt–Jakob disease, prion diseases
- RBD *see* REM sleep behavior disorder
- reduplicative paramnesia 12–13
- reflexes, pathological 306
- REM sleep behavior disorder (RBD) 89
- dementia with Lewy bodies 9–10, 200, 201
 as early symptom (“idiopathic”) 2, 203
 Parkinson’s disease with dementia 203
 pathology 10
 progressive supranuclear palsy 205
 treatment 217, 233, 242
- resting state networks 110
- restless legs syndrome 233, 241
- risk factors, dementia 121–126
- rivastigmine
 Alzheimer’s disease 63, 64
 dementia with Lewy bodies 18–19, 217
 mild cognitive impairment 182
 neuropsychiatric symptoms 95
- Rivermead Behavioural Memory Test (RBMT) 78
- RNA interference (RNAi) 135
- rofecoxib, mild cognitive impairment 182–183
- S-100 protein, CSF 346–347
- salience network 110
- sarcoidosis 354
- scrapie 35–36
- screening, dementia, in oldest-old 258
- secretases 28, 29
 as therapeutic target 65
- seizures, paraneoplastic limbic encephalitis 383, 386
- selective serotonin-reuptake inhibitors (SSRIs) 95
 Alzheimer’s disease 64
 frontotemporal dementia 52, 228
 primary progressive aphasia 284
- selective vulnerability 142, 143
- semantic dementia (SD) (temporal variant frontotemporal dementia; tv-FTD) 46, 48, 227–229, 264–275
 classification 45
 clinical features 5–6, 47, 48, 265–267
 historical background 264–265
 management 229, 273–275
 mental status examination 79–80
 neuroimaging 51, 265, 272–273
 neuropathology 146, 147, 148, 149, 273, 274

Index

- semantic dementia (SD) (cont.)
 neuropsychiatric symptoms 91, 92
 neuropsychological findings 265, 267–272
 prognosis 273
 right temporal variant 265, 266, 267
 selective vulnerability 143
 underlying biology 5
 vs. other primary progressive aphasia variants 283
- semantic knowledge, assessing
 non-verbal 267–268
- semantic memory 264
 corticobasal syndrome 294
 testing in semantic dementia 267
- semantic paraphasias, semantic dementia 283
- senescent forgetfulness
 benign 189
 malignant 189
- senile plaques *see* neuritic plaques
- sensory disturbances
 corticobasal syndrome 206, 207
 dementia with Lewy bodies 202
 as early symptoms 204, 207
 oldest-old 259–260
 Parkinson's disease with dementia 203
- serum biomarkers
 cancer 381
 mild cognitive impairment 178
- short interfering RNA (siRNA) 135
- simultanagnosia, progressive 215–216
- single nucleotide polymorphisms 38
- single-photon emission computed tomography (SPECT) 6, 102–103, 112
 Alzheimer's disease 62, 102–103
 dementia with Lewy bodies 16
 frontotemporal dementia 51
- sleep apnea 2, 201, 241
- sleep disturbances 89
 dementia with Lewy bodies 201–202
 as early symptoms 203–204, 208
 FTDP-17 208
 management 233, 241–242
 Parkinson's disease with dementia 203
 progressive supranuclear palsy 205
 see also REM sleep behavior disorder
- small-cell lung cancer (SCLC) 353, 377, 385–386
- small-vessel disease dementia
 see subcortical vascular dementia
- smoking 124
- social engagement 125
- socially inappropriate behavior 240
- sociopathy, acquired 305
- somnolence, excessive daytime
 see hypersomnia/hypersomnolence
- sortilin-related receptor (SORL1) 58
- SPECT *see* single-photon emission computed tomography
- speech problems
 Alzheimer's disease 59
 as first symptoms 2
 progressive non-fluent aphasia 280
 pure motor speech disorder 284
- spirochaete infections 355
- statins 126
- Steele–Richardson–Olszewski syndrome *see* progressive supranuclear palsy
- stereotyped interests, semantic dementia 266–267
- steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) 354
- striatal encephalitis, paraneoplastic 387–388
- stroke 162
 delirium after 370, 372
 ischemic, in CADASIL 330
 multi-infarct dementia and 303
 post-stroke dementia 302
 subcortical 311–315
 see also cerebral infarction, vascular dementia
- Stroop interference tests 76
- subacute sclerosing panencephalitis 355
- subcortical arteriosclerotic encephalopathy
 see Binswanger's disease
- subcortical dementia 205, 296
- subcortical ischemic vascular dementia (SIVD) 224
- subcortical stroke 311–315
- subcortical vascular dementia (SVaD) 303, 311–315, 316–319
 CADASIL 329
 lacunar type *see* lacunar state
 mixed type 316, 317
 neurological aspects 317–318
 neuropsychiatric aspects 318–319
 neuropsychological aspects 318
 types 316
 vs. Alzheimer's disease 316–317
 white matter type *see* Binswanger's disease
- subcortical vascular mild cognitive impairment (svMCI) 319, 320
- sundowning 242, 368
- symptoms
 first 1–2
 management of target 232–242
 progression 2
- α -synuclein 14–15
 gene mutations (*PARK1/SNCA*) 17–18, 33–34
 immunoreactive inclusions 154
 synergism with β -amyloid 15
 transgenic mice 134
- synucleinopathies 33–34, 213
 pathology 14, 152–154
- syphilis 355
- TAR DNA-binding protein (TDP-43) 33, 49–50, 51
- tau 30–31, 34
 Alzheimer's disease
 pathogenesis 145
 corticobasal degeneration 289
 CSF 62, 178, 346–347
 filamentous deposits 51, 147
 frontotemporal dementia 289
 gene *see* microtubule-associated protein tau, the *MAPT* gene
 inclusions 51, 151
 neurofibrillary tangles 58, 145
 PET 179
 as therapeutic target 65
- tauopathies 34–35, 213–214
 animal models 133–134, 136–137
 dementia-movement disorder 149–152
 pathology 147, 149–152
 progressive non-fluent aphasia 282
- TDP-43 (TAR DNA-binding protein) 33, 49–50, 51

Index

- temporal lobe atrophy, semantic dementia 272
- temporal lobe encephalitis, paraneoplastic 388–389
- terminal end-of-life delirium 370–371
- testicular tumors 387
- tetracyclines 352
- thalamic infarction 313–315
 inferolateral territory 315
 paramedian artery territory 314–315
 tuberthalamic arterial territory 313–314
- thiamine deficiency 356
- thymoma 353, 377
- toxic-metabolic conditions 356–357
- Trail Making Test 76, 258–259
- transgenic invertebrate models 135
- transgenic mice 132–134
- transient brain ischemia 162
- transmissible spongiform encephalopathies (TSEs) 35–36
- trazodone, frontotemporal dementia 52
- treatment of dementia 213–242
- tricyclic antidepressants 95
- trinucleotide repeats 37, 154
- Triopheryma whippellii* 355–356
- ubiquitin–TDP-43 33, 49–50
 neuronal inclusions 147–149
- UCHL1* gene 34
- University of California at San Francisco (UCSF) cognitive battery 3
- urinary incontinence 241
- urinary symptoms 10
- utilization behavior 305
- valosin-containing protein mutations in *VCP* 31–32, 50
- valproate/valproic acid 95, 236
- vascular cognitive impairment with no dementia (VCIND) 303, 319–320
- vascular dementia (VaD) 213, 223–224, 302–320
 clinical features 5–6
 cortical territorial infarction 303–311
 definition and prevalence 302
 diagnosis 224
 diagnostic criteria 302, 320–322
 epidemiology 120
 ischemic–hypoperfusive 310–311
 management 224, 225
 neuroimaging 103
 neuropsychiatric symptoms 90–91, 308, 318–319
 risk factors 121, 122–123
 small-vessel ischemic disease 303, 315–319
 subcortical *see* subcortical vascular dementia
 subtypes 303
 underlying biology 5
 see also cerebrovascular disease
- vascular disease
 rapidly progressing dementias 354
 see also cerebrovascular disease
- vascular mild cognitive impairment 303, 319–320
- vascular smooth muscle cells (VSMCs), changes in CADASIL 334, 336, 337
- VGKC *see* voltage-gated potassium channels
- visual anosognosia 310
- visual deficits
 as first symptoms 2
 oldest-old 259–260
 vascular dementia 309
- visual hallucinations 2, 88
 dementia with Lewy bodies 11–12, 201
 as early symptoms 203
 management 240–241
- visual object agnosia 310
- visuo perceptual dysfunction
 corticobasal syndrome 294
 management 236
- visuo perceptual syndrome, progressive 215–216
- visuospatial abilities, mental status examination 77
- visuospatial dysfunction
 Alzheimer's disease 59
 corticobasal syndrome 294
 management 236
 vascular dementia 307–308, 318
- vitamin B₁ deficiency 356
- vitamin B₁₂ supplements 123
- vitamin C supplements 124
- vitamin deficiencies 356
- vitamin E supplements 124, 127
 mild cognitive impairment 181–182
- voltage-gated potassium channels (VGKC) antibodies 353–354, 378, 379, 382, 386
- von Economo neurons (VENs) 50–51, 148, 149, 150
- voxel-based morphometry (VBM) 105–106
- wandering 88
- Wernicke's aphasia 307
- Wernicke's encephalopathy 356
- Whipple's disease 355–356
- white matter changes
 age-related (ARWMC) 319–320
 genetic aspects 336–337
 subtle, in CADASIL 333–334, 335
- white matter hyperintensities (WMH) 162
 amnesic mild cognitive impairment 164–165
 anatomical basis 165
 CADASIL 332–333
 cognitive impairment and 163
 dorsolateral prefrontal activation and 165–166
 mild cognitive impairment with severe (MCI-WMH) 164–165
- whole genome association (WGA) studies 38
- word alienation 266
- word comprehension 280